Perspective

Nitric Oxide Signaling in Inflammation and Oxidative Stress: Mechanistic Insights and Therapeutic Opportunities

Atefe Yaghoubi[1], **Zohre Aghaei** [2*]

[1] Department of Anatomy, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

[2] Department of Physiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

***Corresponding author:** Zohre Aghaei, Department of Physiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: Zohreh.aghaee2014@gmail.com

Received: March 15, 2026; **Revised:** June 07, 2026; **Accepted**: June 12, 2026; **Published online:** June 14, 2026.

Nexus of Pathophysiology and Therapeutics (NPT). 2026;1(1), https://doi.org/10.22034/npt.2026.1.009

Abstract:

Nitric oxide (NO) is a multifunctional gaseous signaling molecule that plays a central role in maintaining physiological homeostasis while also contributing to diverse pathological processes. Its biological effects are highly context dependent and are shaped by the interplay between nitric oxide synthase (NOS) isoforms, local redox balance, temporal dynamics, cellular environment, and concentration gradients. Under physiological conditions, NO support's vascular function, neuronal communication, and immune regulation through well-coordinated signaling pathways, including cyclic GMP production and post-translational protein modifications. However, under conditions of oxidative stress or sustained inflammatory activation, NO signaling can shift toward the generation of reactive nitrogen species, leading to cellular dysfunction, oxidative injury, and tissue damage. This review highlights the non-redundant roles of NOS isoforms—endothelial (eNOS), neuronal (nNOS), and inducible (iNOS)—as context-specific regulators of NO production, each contributing distinctly to physiological and pathological outcomes. eNOS primarily maintains vascular integrity, nNOS regulates neural signaling, and iNOS drives inflammatory responses, with their dysregulation playing a key role in cardiovascular, neuroinflammatory, oncologic, and renal diseases. Across these systems, the balance between protective and deleterious NO signaling is determined by isoform activity, redox environment, exposure time, and local concentration. Finally, we discuss emerging therapeutic strategies that aim to modulate NO signaling in a more precise and context-aware manner, including isoform-selective targeting, redox modulation, controlled NO delivery systems, and computationally guided drug design. Together, these approaches underscore the importance of integrating mechanistic insight with translational applications to better harness the therapeutic potential of NO while minimizing its cytotoxic effects.

Keywords: Nitric Oxide, Inflammation and Oxidative Stress, NOS Isoforms, iNOS, eNOS



Graphical Abstract. Context-Dependent Nitric Oxide Signaling and Therapeutic Opportunities. This schematic illustrates how NO's effects are determined by isoform specificity, redox environment, cellular context, concentration, and temporal dynamics. Mechanistic understanding of these variables informs targeted therapeutic strategies to harness protective signaling while minimizing cytotoxic outcomes.

Introduction

Nitric oxide (NO) is a small and highly diffusible signaling molecule that plays a fundamental role in both physiological regulation and pathological processes (1). Since its identification as the endothelium-derived relaxing factor, NO has attracted considerable attention because of its involvement in vascular homeostasis, neuronal communication, and immune regulation (2, 3). Through its broad influence on intracellular and intercellular signaling pathways, NO has become recognized as a critical mediator in multiple biological systems (4). Despite its well-established protective functions, the biological effects of NO are remarkably complex and often paradoxical (5, 6). Under physiological conditions, NO contributes to vascular relaxation, suppresses platelet aggregation, and limits excessive inflammatory responses, thereby supporting tissue integrity and normal cellular function (7). In contrast, dysregulated or sustained NO production may promote oxidative and nitrosative stress, leading to cellular dysfunction, cytotoxicity, and tissue damage (8, 9).

The functional outcome of NO signaling is therefore highly dependent on the biological context in which it is generated (10). Factors such as the enzymatic source of NO, duration of exposure, local redox balance, and tissue-specific microenvironment collectively determine whether NO exerts protective or detrimental effects (7, 9). Understanding these context-dependent mechanisms is essential for clarifying the dual nature of NO in health and disease (10). The dual

nature of NO continues to represent a major challenge in both biomedical research and therapeutic development. Although NO has been extensively investigated, the mechanisms that determine whether it acts as a protective mediator or a contributor to tissue injury are not yet fully clarified (7, 8). In many cases, NO has traditionally been viewed as a relatively uniform signaling molecule, without sufficient consideration of factors such as NOS isoform specificity, localized NO gradients, and its interactions with reactive oxygen species (5, 10). This oversimplified perspective limits the accurate interpretation of NO-related signaling and reduces the effectiveness of strategies aimed at targeting NO pathways therapeutically (5).

The purpose of this review is to present an integrated mechanistic perspective on context-dependent NO signaling. Particular emphasis is placed on how NOS isoforms, redox balance, temporal patterns of NO production, and concentration-dependent effects collectively shape the biological consequences of NO activity. By connecting fundamental molecular mechanisms with emerging translational approaches, this review seeks to provide a clearer understanding of how NO signaling contributes to cardiovascular, neurological, inflammatory, and oncologic disorders. In addition, this work discusses how improved insight into the context-specific behavior of NO may support the development of more selective and effective therapeutic interventions. A more precise understanding of NO biology could facilitate the rational design of treatment strategies that preserve the beneficial effects of NO while reducing the risk of oxidative damage and unintended cytotoxicity.

Nitric Oxide Biology: Beyond a Simple Mediator

Nitric oxide (NO) is widely recognized as a gaseous signaling molecule, but its biological functions extend well beyond those of a conventional mediator. As a gasotransmitter, NO diffuses rapidly through cellular membranes, allowing it to coordinate both local and systemic physiological responses (11). Its biological activity is highly dynamic and depends on factors such as concentration, duration of exposure, and the specific cellular environment in which it is produced (1, 12). One of the best-characterized mechanisms of NO signaling involves the activation of soluble guanylate cyclase (sGC), leading to increased intracellular cyclic guanosine monophosphate (cGMP) levels (13, 14). The subsequent activation of cGMP-dependent pathways regulates multiple downstream targets, including protein kinases, ion channels, and transcriptional regulators (15, 16). Through these mechanisms, NO contributes to essential physiological processes such as vascular relaxation, inhibition of platelet activation, and modulation of smooth muscle tone (6).

In addition to cGMP-mediated signaling, NO can directly influence cellular function through several post-translational protein modifications, including S-nitrosylation, nitrosation, and tyrosine nitration (17, 18). These modifications can alter protein structure and activity, thereby affecting enzymatic function, receptor signaling, and intracellular communication pathways. Such regulatory effects highlight the complexity of NO biology and demonstrate that its role extends far beyond a simple diffusible messenger. The dual behavior of NO becomes particularly evident when comparing its functions under physiological and pathological conditions (6). At low concentrations or during transient production, NO generally supports adaptive cellular signaling and contributes to the maintenance of tissue homeostasis (4). Under these conditions, it exerts cytoprotective effects through mechanisms that promote vascular integrity, regulate inflammation, and preserve normal cellular function (6). However, excessive or sustained NO production, particularly in environments enriched

with reactive oxygen species, can shift its role toward cellular injury (19). In such settings, NO readily reacts with superoxide to form reactive nitrogen species such as peroxynitrite (20), which can induce oxidative damage, impair protein function, and ultimately trigger cell death pathways (9, 20).

These contrasting effects emphasize that NO should not be regarded as a uniformly beneficial or harmful molecule (5). Rather, its biological activity is highly dependent on the surrounding molecular and cellular context (21). Factors including the source of NO generation, local redox conditions, duration of exposure, and tissue-specific responses collectively determine the final physiological outcome (5, 19). From a mechanistic perspective, NO is better understood as a context-sensitive signaling regulator rather than a simple diffusible mediator (5). Its effects are shaped by NOS isoform-specific activity, interactions with oxidative pathways, and the characteristics of the local microenvironment (22). Recognizing this complexity is essential not only for understanding the diverse roles of NO in health and disease but also for developing therapeutic strategies capable of selectively enhancing its beneficial actions while limiting its pathological consequences (23).

NOS Isoforms as Context-Dependent Regulators of NO Signaling

Nitric oxide synthesis is mediated by three major nitric oxide synthase (NOS) isoforms—endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). Although all isoforms catalyze the conversion of L-arginine into NO and citrulline, they differ substantially in their regulatory mechanisms, tissue distribution, and biological functions (10). These differences are central to understanding the context-dependent and often paradoxical effects of NO signaling in both physiology and disease (6).

A. eNOS: Maintaining Vascular Homeostasis

Endothelial NOS is constitutively expressed primarily in vascular endothelial cells, where its activity is tightly regulated by intracellular calcium levels, calmodulin signaling, and mechanical stimuli such as shear stress (6, 10). Under physiological conditions, eNOS-derived NO plays a crucial role in preserving vascular homeostasis by promoting vasodilation, inhibiting platelet aggregation, and reducing leukocyte adhesion to the endothelium (24). Through these actions, eNOS contributes to an anti-inflammatory and vasoprotective microenvironment (25). The functional state of eNOS is strongly influenced by the local redox balance (26). In conditions associated with oxidative stress, eNOS may become uncoupled, resulting in the production of superoxide rather than NO. This shift transforms eNOS from a protective signaling enzyme into a contributor to oxidative injury and endothelial dysfunction (27). Such alterations are closely associated with the pathogenesis of cardiovascular disorders, including hypertension, atherosclerosis, and chronic vascular inflammation (28). Taken together, eNOS functions as a key regulator of endothelial integrity, and disruption of its normal signaling represents a critical step in the development of vascular disease (24).

B. nNOS: Regulator of Neuronal Signaling

Neuronal NOS (nNOS) is primarily expressed in neurons and, to a lesser extent, in skeletal muscle tissue, where it plays an important role in neurotransmission, synaptic plasticity, and neurovascular regulation (29-31). Under physiological conditions, nNOS-derived NO contributes to normal neuronal communication and supports processes involved in learning, memory formation, and adaptive neural responses (32, 33). Its signaling activity is tightly controlled within

specialized cellular microdomains, allowing precise modulation of neuronal function (30). However, dysregulated nNOS activation can become detrimental, particularly during excitotoxic events associated with excessive glutamate stimulation or intracellular calcium overload. In these settings, elevated NO production may react with superoxide radicals to generate peroxynitrite and other reactive nitrogen species, leading to oxidative injury, mitochondrial dysfunction, and neuronal cell death (9, 34). These observations illustrate how the biological effects of nNOS-derived NO are strongly influenced by cellular context, spatial localization, and the duration and intensity of signaling (31).

C. iNOS: Driver of Sustained Inflammatory Signaling

Inducible NOS (iNOS) differs fundamentally from the constitutively expressed NOS isoforms in both regulation and function. Its expression is induced in response to inflammatory cytokines, microbial products, and various cellular stress signals, primarily in immune cells but also in endothelial cells and other tissues under pathological conditions. Once activated, iNOS generates large and sustained amounts of NO, which can contribute to antimicrobial and cytotoxic defense mechanisms (35, 36). Although this response is beneficial during host defense, prolonged or excessive iNOS activation may promote tissue injury and inflammatory damage. Increased iNOS activity has been implicated in numerous pathological conditions, including sepsis, chronic inflammatory disorders, and ischemia–reperfusion injury (8, 36). Unlike eNOS and nNOS, iNOS activity is relatively independent of intracellular calcium fluctuations, allowing continuous NO production once the enzyme is expressed (10). This distinct regulatory pattern further highlights the isoform-specific nature of NO signaling and its importance in determining whether NO exerts protective or pathological effects (37).

NOS Isoforms Are Functionally Distinct

Taken together, current evidence indicates that NOS isoforms are not functionally redundant but instead operate as specialized signaling systems adapted to distinct physiological and pathological settings (37). Endothelial NOS (eNOS) is primarily involved in maintaining vascular homeostasis and endothelial integrity, whereas neuronal NOS (nNOS) regulates neuronal communication and neuromuscular signaling (10). In contrast, inducible NOS (iNOS) is predominantly associated with inflammatory activation and sustained immune responses. The diverse functions of these isoforms help explain the complex and sometimes opposing effects of NO in different tissues and disease states (38). Recognizing the isoform-specific nature of NO signaling is particularly important for therapeutic development (39). Effective interventions should aim to preserve or enhance protective NO signaling while limiting excessive or pathological NO production (37, 40). Such an approach requires consideration of tissue specificity, disease progression, and the surrounding oxidative environment (41). Therefore, understanding the distinct regulatory and functional characteristics of each NOS isoform provides a foundation for more selective and context-oriented therapeutic strategies (38).

Context-Dependent Mechanisms of NO Signaling

The biological effects of nitric oxide are highly dependent on the molecular and cellular context in which signaling occurs (1). Multiple factors—including redox balance, local cellular conditions, duration of NO exposure, and concentration gradients—collectively influence the downstream consequences of NO activity (26, 42). These

interacting variables ultimately determine whether NO promotes adaptive and cytoprotective signaling pathways or contributes to oxidative injury and cellular dysfunction (43).

A. Redox Environment

The redox state of the cellular environment is a key determinant of nitric oxide (NO) bioactivity (1, 26). Under conditions of oxidative stress, NO readily reacts with superoxide (O_2^-) to generate peroxynitrite ($ONOO^-$), a highly reactive oxidant that can damage lipids, proteins, and nucleic acids (9, 26). In this context, an oxidative shift effectively redirects NO signaling toward cytotoxic outcomes, limiting its physiological signaling capacity (43, 44). By contrast, in a more reducing environment, NO is more likely to engage in canonical signaling pathways, including activation of soluble guanylate cyclase (sGC) and S-nitrosylation of specific protein targets, thereby supporting adaptive and protective cellular responses (1, 43). These opposing outcomes highlight the importance of redox balance in shaping whether NO acts as a signaling mediator or a source of cellular injury, and they also point to the potential value of redox-modulating strategies in disease settings (44).

B. Cellular Context

The biological effects of NO also vary significantly depending on the cell type in which it is produced (6). In endothelial cells, NO generated by eNOS plays a protective role by promoting vasodilation, reducing leukocyte adhesion, and maintaining overall vascular stability (45). In neurons, nNOS-derived NO contributes to normal synaptic plasticity and neurocommunication, but excessive production can lead to excitotoxic damage and neuronal dysfunction (30). In immune cells, iNOS-derived NO is part of the host defense system, supporting microbial killing and inflammatory signaling, although sustained or excessive activity can also result in collateral tissue injury (46). This clear cell-type specificity emphasizes that NO signaling cannot be interpreted in isolation, but must instead be understood within the broader cellular and tissue context in which it operates (11).

C. Temporal Dynamics

The timing of nitric oxide (NO) production is a key factor in determining its biological effects. During the early stages of acute inflammation, NO signaling often contributes to cytoprotection and supports the resolution of injury (6). However, when NO production becomes sustained or persists into later phases, it can shift toward promoting tissue damage and exacerbating inflammatory responses (47). Brief, transient bursts of NO are generally associated with adaptive signaling and can activate transcriptional programs that support cellular repair and survival (42). In contrast, prolonged exposure to elevated NO levels is more likely to induce oxidative stress, impair mitochondrial function, and trigger apoptotic pathways (48). These time-dependent differences highlight the importance of distinguishing between acute and chronic NO signaling when interpreting its role in disease (5).

D. Concentration Dependency

The biological effects of NO are also strongly dependent on its local concentration (11). At low, physiological levels, NO primarily engages classical signaling pathways such as cyclic GMP (cGMP) production and protein S-nitrosylation, both of which support normal cellular homeostasis (6). At higher concentrations, particularly those generated during strong iNOS activation, NO can exceed the capacity of antioxidant defenses (8). Under these conditions, it readily reacts with superoxide to form reactive nitrogen species, leading to oxidative and nitrosative stress (9). This concentration-dependent transition from signaling mediator to cytotoxic agent underscores the need for

careful control of NO bioavailability in therapeutic settings, with the aim of preserving its beneficial functions while limiting potential harm (6, 11).

Conceptual Framework

When these factors are considered together, nitric oxide (NO) signaling can be understood as a highly context-sensitive network rather than a linear pathway (44). Its biological outcome is shaped by the combined influence of NOS isoform activity, redox status, cellular environment, duration of exposure, and local concentration. Within this integrated framework (Figure 1), NO operates as a dynamic regulator whose effects shift depending on the surrounding biochemical and physiological conditions (6, 49). Mapping NO signaling in this way provides a useful basis for interpreting its dual behavior and for anticipating whether it will contribute to tissue protection or pathology. This systems-level perspective also supports more rational therapeutic design by linking molecular mechanisms to disease-specific outcomes (44).

Disease-Specific Mechanistic Outcomes

A. Cardiovascular Disease

In the cardiovascular system, NO signaling is largely dominated by endothelial NOS (eNOS). Under normal physiological conditions, eNOS-derived NO is essential for maintaining vascular tone, preventing platelet aggregation, and limiting leukocyte adhesion to the endothelium (5). However, in disease states such as oxidative stress, hyperglycemia, or dyslipidemia, eNOS function can become impaired or uncoupled, leading to reduce NO availability and increased superoxide production, which contributes to endothelial dysfunction (27, 50). At the same time, inflammatory stimulation can induce iNOS expression, resulting in sustained high levels of NO that readily interact with superoxide to form peroxynitrite and further damage vascular structures (8). The interplay between diminished eNOS activity and excessive iNOS-derived NO is therefore a key determinant of disease progression in conditions such as hypertension, atherosclerosis, and heart failure (44).

B. Neuroinflammation

Within the central nervous system, neuronal NOS (nNOS) plays an important role in regulating neurotransmission and neurovascular coupling. Under physiological conditions, this supports normal synaptic function and neural signaling (33, 51). However, during pathological events such as excitotoxicity, stroke, or neurodegenerative disease, excessive nNOS activation can lead to overproduction of NO (52). This often results in the formation of peroxynitrite and increased protein nitration, which contribute to synaptic dysfunction and neuronal cell death (9). In parallel, induction of iNOS in glial cells can further amplify inflammatory signaling and exacerbate neurotoxicity (53, 54). These processes highlight the importance of both timing and cellular context, where transient NO signaling may be protective, while sustained or excessive production becomes damaging to neural tissue (55).

C. Cancer

In cancer biology, nitric oxide (NO) has been shown to exert both tumor-promoting and tumor-suppressing effects, depending on its context (4, 56). At low and transient levels, NO may support tumor progression by inhibiting apoptosis and stimulating angiogenic pathways, thereby facilitating tumor growth and survival (57). In contrast, sustained high levels of NO, often produced by iNOS-expressing immune or tumor cells, can lead to DNA damage, growth arrest, and induction of apoptosis, ultimately suppressing tumor proliferation (58). This apparent contradiction is largely driven by differences in the

tumor microenvironment, NOS isoform expression, and local redox conditions (57). Understanding these context-dependent effects is essential for developing therapeutic strategies that may involve selective modulation of NOS activity, controlled NO delivery, or combination approaches targeting oxidative stress pathways (23).

D. Kidney Ischemia–Reperfusion Injury

Renal ischemia–reperfusion (I/R) injury provides another clear example of the context-dependent behavior of NO (59). Under physiological conditions, eNOS-derived NO helps maintain renal microcirculation, improves blood flow, and reduces leukocyte adhesion, thereby contributing to tissue protection (60). However, during reperfusion, inflammatory signaling often induces iNOS expression, leading to excessive NO production (59). This high-output NO can interact with superoxide to form peroxynitrite, which contributes to tubular cell injury and oxidative stress (20, 61). The imbalance between reduced eNOS activity and excessive iNOS-derived NO plays a central role in the development of acute kidney injury (62). These mechanisms suggest that therapeutic strategies aimed at enhancing eNOS function while limiting iNOS induction may offer protective benefits in ischemia–reperfusion settings (20, 63).

Summary of Disease Contexts

Across cardiovascular, neurological, oncological, and renal diseases, the effects of nitric oxide are governed by a combination of isoform specificity, redox environment, concentration, and temporal dynamics (6, 64, 65). Recognizing these interacting factors provides a clearer mechanistic basis for interpreting NO biology and helps identify more precise points for therapeutic intervention, linking molecular understanding with translational applications (44, 66).

Therapeutic Opportunities

A deeper understanding of nitric oxide (NO) signaling has opened several promising avenues for therapeutic intervention (41, 66). These strategies largely focus on modulating NOS isoform activity, restoring redox balance, and achieving controlled, context-specific NO delivery (10). Effective translation of these concepts into clinical approaches requires careful consideration of isoform function, concentration-dependent effects, temporal dynamics, and tissue-specific signaling environments (44, 66).

A. NOS Isoform Targeting

One of the most direct therapeutic strategies involves selective modulation of NOS isoforms (38, 67). In conditions such as sepsis, chronic inflammation, and ischemia–reperfusion injury, inhibition of inducible NOS (iNOS) may help reduce excessive NO production and limit the formation of reactive nitrogen species like peroxynitrite, thereby decreasing tissue damage (68, 69). On the other hand, enhancing endothelial NOS (eNOS) activity—either pharmacologically or through interventions that increase endothelial shear stress, such as exercise—can help restore vascular function, improve vasodilation, and reduce vascular inflammation (70, 71). Importantly, isoform-specific targeting offers a more refined approach compared to non-selective NOS inhibition, helping to preserve beneficial NO signaling while minimizing unwanted systemic effects (10).

B. Redox Modulation

Because NO signaling is closely linked to cellular redox balance, strategies aimed at correcting oxidative stress are also highly relevant (65). Antioxidant therapies may help prevent eNOS uncoupling and reduce the formation of peroxynitrite, thereby maintaining protective NO signaling pathways (41, 72). In addition,

peroxynitrite scavengers can directly neutralize reactive nitrogen species, limiting oxidative and nitrosative damage without significantly disrupting physiological NO functions (8, 9). Together, these approaches leverage the interaction between NO and reactive oxygen species to shift signaling outcomes toward cytoprotection rather than injury (65).

C. Controlled NO Donors

When carefully regulated, exogenous nitric oxide (NO) delivery can be used to support cytoprotective signaling in a controlled manner. Slow-releasing or tissue-targeted NO donors may help restore NO availability in conditions characterized by endothelial dysfunction, such as cardiovascular disease or renal ischemia, without reaching levels that promote oxidative or nitrosative stress (41). More advanced delivery systems, including nanoparticle-based carriers and hydrogel platforms, further improve spatial and temporal control, allowing NO to be released directly at the target site and at physiologically relevant concentrations. This precision helps maximize therapeutic benefit while reducing the risk of off-target or cytotoxic effects (73).

D. Emerging Strategies

Recent advances in biomedical engineering and computational approaches have expanded the possibilities for NO-based therapies (74). Nanotechnology-enabled delivery systems can now be designed to release NO or modulate NOS activity in a cell-specific and highly controlled manner (75). At the same time, artificial intelligence–driven drug design is increasingly being used to predict isoform selectivity, redox interactions, and tissue-specific responses, which can significantly accelerate the development of targeted interventions (76). In addition, combination strategies that integrate NOS modulation, redox regulation, and controlled NO donation may offer synergistic effects while minimizing adverse outcomes (77).

Translating NO Biology into Therapeutic Strategies

Overall, these therapeutic approaches demonstrate how a detailed mechanistic understanding of NO signaling can inform the rational development of targeted therapeutic interventions (44). By integrating knowledge of disease-specific NO dynamics, it becomes possible to design interventions that enhance beneficial signaling pathways while limiting cytotoxic effects (6). This framework reinforces the idea that advances in basic molecular understanding can be effectively translated into more precise and rational therapeutic strategies, bridging fundamental biology with clinical practice (65).

Challenges and Controversies

Despite considerable progress in understanding nitric oxide (NO) biology and encouraging preclinical findings, translating this knowledge into effective therapies has proven difficult (78). In clinical settings, both NOS inhibitors and NO-based therapies have frequently shown limited success, largely due to poor selectivity, systemic adverse effects, and an incomplete integration of NO's context-dependent behavior (41). For example, broad inhibition of iNOS can interfere with essential host defense mechanisms, while non-specific NO donors may lead to unwanted hypotension, increased oxidative stress, or direct tissue toxicity. A major limitation in translational research is the tendency of experimental models to overlook the complexity of in vivo conditions. Many in vitro and animal studies fail to fully reproduce the combined influence of NOS isoform interplay, redox imbalance, and disease-stage variability observed in human pathology (8, 79). As a result, interventions that appear effective in controlled models may

produce inconsistent or even adverse outcomes in clinical trials (80).

In addition, the lack of reliable biomarkers and effective patient stratification strategies remains a significant barrier (81). Without the ability to identify patients with specific patterns of NO dysregulation or redox imbalance, it becomes difficult to tailor therapies with sufficient precision (82). Although emerging approaches such as tissue-targeted NO delivery systems, redox-based interventions, and AI-guided prediction models offer promising directions, they still require extensive validation before clinical implementation (73, 83). Overall, these challenges reinforce a central principle of NO biology: therapeutic outcomes are highly dependent on mechanistic context (84). A detailed understanding of isoform-specific signaling, temporal dynamics, and disease-stage progression is not simply of academic interest but is essential for developing safe and effective interventions that harness the beneficial aspects of NO while minimizing its harmful effects (2).

Conclusion

Nitric oxide (NO) is a highly context-dependent signaling molecule whose biological effects are determined by the interplay of NOS isoform activity, redox status, concentration gradients, cellular environment, and temporal dynamics. This integrated regulatory network explains the dual nature of NO, which can support vascular homeostasis, neuronal communication, and immune defense under physiological conditions, while contributing to oxidative stress, inflammation, and tissue injury when dysregulated. The diverse roles of NO across cardiovascular, neurological, inflammatory, oncological, and renal disorders highlight the importance of considering biological context when interpreting its functions in health and disease. Collectively, current evidence supports the view that NO acts as a dynamic regulator rather than a uniformly protective or harmful mediator, providing a unifying framework for understanding its complex and often paradoxical biological effects.

Mechanistic and Translational Relevance

The context-dependent nature of nitric oxide signaling provides an important mechanistic basis for therapeutic development. Understanding how NOS isoforms, redox interactions, temporal dynamics, and tissue-specific factors shape NO activity helps explain the variability of its effects across physiological and pathological conditions. These insights support the design of more targeted and predictable interventions, including enhancement of eNOS-mediated signaling, selective suppression of pathological iNOS activity, and controlled NO delivery strategies. By linking molecular mechanisms to disease-specific outcomes, this framework moves beyond empirical approaches and facilitates the development of more precise therapeutic interventions. Ultimately, the integration of mechanistic understanding with translational application highlights how context-oriented NO biology can guide future clinical innovation.

Reference

1. Mazuryk O, Gurgul I, Oszajca M, Polaczek J, Kieca K, Bieszczad-Żak E, et al. Nitric oxide signaling and sensing in age-related diseases. Antioxidants. 2024;13(10):1213. https://doi.org/10.3390/antiox13101213.

2. Carlström M, Weitzberg E, Lundberg JO. Nitric oxide signaling and regulation in the cardiovascular system: recent advances. Pharmacological Reviews. 2024;76(6):1038-62. https://doi.org/10.1124/pharmrev.124.001060.

3. Nappi F, Fiore A, Masiglat J, Cavuoti T, Romandini M, Nappi P, et al. Endothelium-derived relaxing factors and endothelial function: A

systematic review. Biomedicines. 2022;10(11):2884. https://doi.org/10.3390/biomedicines10112884.

4. Soundararajan L, Dharmarajan A, Samji P. Regulation of pleiotropic physiological roles of nitric oxide signaling. Cellular signalling. 2023;101:110496. https://doi.org/10.1016/j.cellsig.2022.110496.

5. Farah C, Michel LY, Balligand J-L. Nitric oxide signalling in cardiovascular health and disease. Nature Reviews Cardiology. 2018;15(5):292-316. https://doi.org/10.1038/nrcardio.2017.224.

6. Lundberg JO, Weitzberg E. Nitric oxide signaling in health and disease. Cell. 2022;185(16):2853-78. https://doi.org/10.1016/j.cell.2022.06.010.

7. Carlström M. Nitric oxide signalling in kidney regulation and cardiometabolic health. Nature reviews nephrology. 2021;17(9):575-90. https://doi.org/10.1038/s41581-021-00429-z.

8. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiological reviews. 2007;87(1):315-424. https://doi.org/10.1152/physrev.00029.2006.

9. Prolo C, Piacenza L, Radi R. Peroxynitrite: a multifaceted oxidizing and nitrating metabolite. Current Opinion in Chemical Biology. 2024;80:102459. https://doi.org/10.1016/j.cbpa.2024.102459.

10. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. European heart journal. 2012;33(7):829-37. https://doi.org/10.1093/eurheartj/ehr304.

11. Andrabi SM, Sharma NS, Karan A, Shahriar SS, Cordon B, Ma B, et al. Nitric oxide: physiological functions, delivery, and biomedical applications. Advanced Science. 2023;10(30):2303259. https://doi.org/10.1002/advs.202303259.

12. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radical Biology and Medicine. 2008;45(1):18-31. https://doi.org/10.1016/j.freeradbiomed.2008.03.020.

13. Stuehr DJ, Misra S, Dai Y, Ghosh A. Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase. Journal of Biological Chemistry. 2021;296:100336.. https://doi.org/10.1016/j.jbc.2021.100336.

14. Sharina I, Martin E. Cellular factors that shape the activity or function of nitric oxide-stimulated soluble guanylyl cyclase. Cells. 2023;12(3):471. https://doi.org/10.3390/cells12030471.

15. Francis SH, Busch JL, Corbin JD. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacological reviews. 2010;62(3):525-63. https://doi.org/10.1124/pr.110.002907.

16. Numata G, Takimoto E. Cyclic GMP and PKG signaling in heart failure. Frontiers in pharmacology. 2022;13:792798. https://doi.org/10.3389/fphar.2022.792798.

17. Li Z, Huang Y, Lv B, Du J, Yang J, Fu L, et al. Gasotransmitter-Mediated Cysteinome Oxidative Posttranslational Modifications: Formation, Biological Effects, and Detection. Antioxidants & Redox Signaling. 2023;40(1-3):145-67. https://doi.org/10.1089/ars.2023.0407.

18. Stomberski CT, Hess DT, Stamler JS. Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling. Antioxidants & redox signaling. 2019;30(10):1331-51. https://doi.org/10.1089/ars.2017.7403.

19. Münzel T, Daiber A. Vascular redox signaling, endothelial nitric oxide synthase uncoupling, and endothelial dysfunction in the setting of transportation noise exposure or chronic treatment with organic nitrates. Antioxidants & Redox Signaling. 2023;38(13-15):1001-21. https://doi.org/10.1089/ars.2023.0006.

20. Szabó C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of

therapeutics. Nature reviews Drug discovery. 2007;6(8):662-80.
https://doi.org/10.1038/nrd2222.

21. Dent MR, DeMartino AW, Tejero J, Gladwin MT. Endogenous hemoprotein-dependent signaling pathways of nitric oxide and nitrite. Inorganic chemistry. 2021;60(21):15918-40.
https://doi.org/10.1021/acs.inorgchem.1c01048.

22. Roy R, Wilcox J, Webb AJ, O'Gallagher K. Dysfunctional and dysregulated nitric oxide synthases in cardiovascular disease: mechanisms and therapeutic potential. International journal of molecular sciences. 2023;24(20):15200.
https://doi.org/10.3390/ijms242015200.

23. Sinha BK. Can nitric oxide-based therapy be improved for the treatment of cancers? A perspective. International Journal of Molecular Sciences. 2023;24(17):13611.
https://doi.org/10.3390/ijms241713611.

24. Heiss C, Rodriguez-Mateos A, Kelm M. Central role of eNOS in the maintenance of endothelial homeostasis. Antioxidants & redox signaling. 2015;22(14):1230-42.
https://doi.org/10.1089/ars.2014.6158.

25. Rafea R, Siragusa M, Fleming I. The Ever-Expanding Influence of the Endothelial Nitric Oxide Synthase. Basic & clinical pharmacology & toxicology. 2025;136(5):e70029.
https://doi.org/10.1111/bcpt.70029.

26. Sies H, Mailloux RJ, Jakob U. Fundamentals of redox regulation in biology. Nature Reviews Molecular Cell Biology. 2024;25(9):701-19.
https://doi.org/10.1038/s41580-024-00730-2.

27. Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cellular & molecular biology letters. 2023;28(1):21.
https://doi.org/10.1186/s11658-023-00423-2.

28. Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Frontiers in medicine. 2022;8:798958.
https://doi.org/10.3389/fmed.2021.798958.

29. Zhou L, Zhu D-Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric oxide. 2009;20(4):223-30.
https://doi.org/10.1016/j.niox.2009.03.001.

30. Maccallini C, Amoroso R. Neuronal nitric oxide synthase and post-translational modifications in the development of central nervous system diseases: Implications and regulation. Molecules. 2023;28(18):6691.
https://doi.org/10.3390/molecules28186691.

31. Ahn SJ, Anfray A, Anrather J, Iadecola C. Calcium transients in nNOS neurons underlie distinct phases of the neurovascular response to barrel cortex activation in awake mice. Journal of Cerebral Blood Flow & Metabolism. 2023;43(10):1633-47.
https://doi.org/10.1177/0271678X231173175.

32. Hardingham N, Dachtler J, Fox K. The role of nitric oxide in pre-synaptic plasticity and homeostasis. Frontiers in cellular neuroscience. 2013;7:190.
https://doi.org/10.3389/fncel.2013.00190.

33. Bahdar ZI, Abu-El-Rub E, Almazari R, Alzu'bi A, Al-Zoubi RM. The molecular mechanism of nitric oxide in memory consolidation and its role in the pathogenesis of memory-related disorders. Neurogenetics. 2025;26(1):22.
https://doi.org/10.1007/s10048-025-00803-0.

34. Wang J, Swanson RA. Superoxide and non-ionotropic signaling in neuronal excitotoxicity. Frontiers in neuroscience. 2020;4:861.
https://doi.org/10.3389/fnins.2020.00861.

35. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric oxide. 2010;23(2):75-93.
https://doi.org/10.1016/j.niox.2010.04.007.

36. Cinelli MA, Do HT, Miley GP, Silverman RB. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Medicinal research reviews. 2020;40(1):158-89. https://doi.org/10.1002/med.21599.

37. Farahani A, Farahani A, Kashfi K, Ghasemi A. Inducible nitric oxide synthase (iNOS): More than an inducible enzyme? Rethinking the classification of NOS isoforms. Pharmacological research. 2025;216:107781. https://doi.org/10.1016/j.phrs.2025.107781.

38. Kim ME, Lee JS. Advances in the regulation of inflammatory mediators in nitric oxide synthase: implications for disease modulation and therapeutic approaches. International journal of molecular sciences. 2025;26(3):1204. https://doi.org/10.3390/ijms26031204.

39. Maccallini C, Budriesi R, De Filippis B, Amoroso R. Advancements in the research of new modulators of nitric oxide synthases activity. International Journal of Molecular Sciences. 2024;25(15):8486. https://doi.org/10.3390/ijms25158486.

40. Tabish TA, Crabtree MJ, Townley HE, Winyard PG, Lygate CA. Nitric oxide releasing nanomaterials for cardiovascular applications. Basic to Translational Science. 2024;9(5):691-709. https://doi.org/10.1016/j.jacbts.2023.07.017.

41. Li H, Förstermann U, Xia N, Kuntic M, Münzel T, Daiber A. Pharmacological targeting of endothelial nitric oxide synthase dysfunction and nitric oxide replacement therapy. Free Radical Biology and Medicine. 2025;237:455-72. https://doi.org/10.1016/j.freeradbiomed.2025.06.009.

42. Gantner BN, LaFond KM, Bonini MG. Nitric oxide in cellular adaptation and disease. Redox Biology. 2020;34:101550. https://doi.org/10.1016/j.redox.2020.101550.

43. Belenichev I, Popazova O, Bukhtiyarova N, Savchenko D, Oksenych V, Kamyshnyi O. Modulating nitric oxide: implications for cytotoxicity and cytoprotection. Antioxidants. 2024;13(5):504. https://doi.org/10.3390/antiox13050504.

44. Venkatesan S, Smirne C, Aquino CI, Surico D, Remorgida V, Ola Pour MM, et al. Nitric Oxide Signaling in Cardiovascular Physiology and Pathology: Mechanisms, Dysregulation, and Therapeutic Frontiers. International Journal of Molecular Sciences. 2026;27(2):629. https://doi.org/10.3390/ijms27020629.

45. Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric oxide and endothelial dysfunction. Critical care clinics. 2020;36(2):307-21. https://doi.org/10.1016/j.ccc.2019.12.009.

46. Spiller F, Formiga RO, da Silva Coimbra JF, Alves-Filho JC, Cunha TM, Cunha FQ. Targeting nitric oxide as a key modulator of sepsis, arthritis and pain. Nitric Oxide. 2019;89:32-40. https://doi.org/10.1016/j.niox.2019.04.011.

47. Kumar S, Dikshit M. Nitric oxide: Regulation and function in neutrophil immune responses. Antioxidants & Redox Signaling. 2024;40(16-18):998-1024. https://doi.org/10.1089/ars.2022.0220.

48. Poderoso JJ, Helfenberger K, Poderoso C. The effect of nitric oxide on mitochondrial respiration. Nitric oxide. 2019;88:61-72. https://doi.org/10.1016/j.niox.2019.04.005.

49. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nature reviews Drug discovery. 2015;14(9):623-41. https://doi.org/10.1038/nrd4623.

50. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circulation research. 2017;120(4):713-35. https://doi.org/10.1161/CIRCRESAHA.116.309326.

51. Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and

dementia. The Neuroscientist. 2010;16(4):435-52. https://doi.org/10.1177/1073858410366481.

52. Anwar A, Yameen D, Masood M, Parvez S, Haque MM. Neuronal Nitric Oxide Synthase (nNOS) uncoupling in ischemic stroke: Mechanisms of oxidative/nitrosative stress and opportunities for neuroprotection: A review. International Journal of Biological Macromolecules. 2025:148589. https://doi.org/10.1016/j.ijbiomac.2025.148589.

53. Ghasemi M, Fatemi A. Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases. Neuroscience & Biobehavioral Reviews. 2014;45:168-82. https://doi.org/10.1016/j.neubiorev.2014.06.002.

54. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nature Reviews Neurology. 2021;17(3):157-72. https://doi.org/10.1038/s41582-020-00435-y.

55. Tripathi MK, Kartawy M, Amal H. The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders. Redox Biology. 2020;34:101567. https://doi.org/10.1016/j.redox.2020.101567.

56. Panneerselvan P, Vasanthakumar K, Muthuswamy K, Krishnan V, Subramaniam S. Insights on the functional dualism of nitric oxide in the hallmarks of cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023;1878(6):189001. https://doi.org/10.1016/j.bbcan.2023.189001.

57. Reddy TP, Glynn SA, Billiar TR, Wink DA, Chang JC. Targeting nitric oxide: say NO to metastasis. Clinical Cancer Research. 2023;29(10):1855-68. https://doi.org/10.1158/1078-0432.CCR-22-2791.

58. Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn SA. The role of nitric oxide in cancer: master regulator or NOt? International journal of molecular sciences. 2020;21(24):9393. https://doi.org/10.3390/ijms21249393.

59. Lee H-M, Choi JW, Choi MS. Role of nitric oxide and protein S-nitrosylation in ischemia-reperfusion injury. Antioxidants. 2021;11(1):57. https://doi.org/10.3390/antiox11010057.

60. Hang X, Ma J, Wei Y, Wang Y, Zang X, Xie P, et al. Renal microcirculation and mechanisms in diabetic kidney disease. Frontiers in Endocrinology. 2025;16:1580608. https://doi.org/10.3389/fendo.2025.1580608.

61. Nieuwenhuijs-Moeke GJ, Pischke SE, Berger SP, Sanders JSF, Pol RA, Struys MM, et al. Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair. Journal of clinical medicine. 2020;9(1):253. https://doi.org/10.3390/jcm9010253.

62. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nature reviews Disease primers. 2021;7(1):52. https://doi.org/10.1038/s41572-021-00284-z.

63. Ergin B, Akin S, Ince C. Kidney microcirculation as a target for innovative therapies in AKI. Journal of Clinical Medicine. 2021;10(18):4041. https://doi.org/10.3390/jcm10184041.

64. Xu Y, Wang X, Zhou X, Peng L, Yuan J, Zhang Y, et al. Nitric oxide-mediated S-Nitrosylation contributes to signaling transduction in human physiological and pathological status. International Journal of Molecular Medicine. 2025;56(4):152. https://doi.org/10.3892/ijmm.2025.5593.

65. Li B, Ming H, Qin S, Nice EC, Dong J, Du Z, et al. Redox regulation: mechanisms, biology and therapeutic targets in diseases. Signal Transduction and Targeted Therapy. 2025;10(1):72. https://doi.org/10.1038/s41392-024-02095-6.

66. Yu H, He Z, Liu B, Du T, Wang H-Y, Liu Y. Recent advances in nitric oxide delivery systems for precision therapeutics. Chinese Chemical Letters.

2025:112225.
https://doi.org/10.1016/j.cclet.2025.112225.

67. Ye H, Zhang C, Zhang Y, Wu J, Huang Z. S-Nitrosation-Based Target Discovery and Drug Development: Toward a Nitric Oxide Drug 2.0 Paradigm. Journal of Medicinal Chemistry. 2026;69(3):2002-5.
https://doi.org/10.1021/acs.jmedchem.6c00247.

68. Anaya-Prado R, Canseco-Villegas AI, Anaya-Fernández R, Anaya-Fernandez MM, Guerrero-Palomera MA, Guerrero-Palomera C, et al. Role of nitric oxide in cerebral ischemia/reperfusion injury: a biomolecular overview. World Journal of Clinical Cases. 2025;13(10):101647.
https://doi.org/10.12998/wjcc.v13.i10.101647.

69. Sharawy N, Lehmann C. Molecular mechanisms by which iNOS uncoupling can induce cardiovascular dysfunction during sepsis: role of posttranslational modifications (PTMs). Life sciences. 2020;255:117821.
https://doi.org/10.1016/j.lfs.2020.117821.

70. Iwamoto E, Sakamoto R, Casey DP. Optimizing cerebrovascular endothelial health through shear stress modulation. Experimental physiology. 2025.
https://doi.org/10.1113/EP092668.

71. Mueller BJ, Roberts MD, Mobley CB, Judd RL, Kavazis AN. Nitric oxide in exercise physiology: Past and present perspectives. Frontiers in Physiology. 2025;15:1504978.
https://doi.org/10.3389/fphys.2024.1504978.

72. Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nature Reviews Molecular Cell Biology. 2024;25(1):13-33.
https://doi.org/10.1038/s41580-023-00645-4.

73. Choi S-H, Han CY, Cho KJ, No K, Kim J. Engineering delivery platforms for controlled nitric oxide release. Biomaterials Science. 2026.
https://doi.org/10.1039/d5bm01825k.

74. Xu G, Su Y, Chen S, Wang S, Wu J, Li S, et al. Ultrasound-Activated Nitric Oxide Release Nanoplatforms and Their Biomedical Applications. ACS Applied Bio Materials. 2025;8(8):6635-46.
https://doi.org/10.1021/acsabm.5c00892.

75. Tang Y, Li Q, Zhou Z, Bai H, Xiao N, Xie J, et al. Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer. Journal of Nanobiotechnology. 2024;22(1):674.
https://doi.org/10.1186/s12951-024-02929-z.

76. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery. 2019;18(6):463-77.
https://doi.org/10.1038/s41573-019-0024-5.

77. Gonzalez M, Clayton S, Wauson E, Christian D, Tran Q-K. Promotion of nitric oxide production: mechanisms, strategies, and possibilities. Frontiers in Physiology. 2025;16:1545044.
https://doi.org/10.3389/fphys.2025.1545044.

78. Nunes RS, Mariano KCF, Pieretti JC, Dos Reis RA, Seabra AB. Innovative nitric oxide-releasing nanomaterials: Current progress, trends, challenges, and perspectives in cardiovascular therapies. Nitric Oxide. 2025;156:67-81.
https://doi.org/10.1016/j.niox.2025.03.004.

79. Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of translational medicine. 2018;16(1):304.
https://doi.org/10.1186/s12967-018-1678-1.

80. Dirnagl U, Bannach-Brown A, McCann S. External validity in translational biomedicine: understanding the conditions enabling the cause to have an effect. EMBO Molecular Medicine. 2022;14(2):EMMM202114334.
https://doi.org/10.15252/emmm.202114334.

81. Huber C, Zinserling J, Benda N, Vetter T, Rueckbeil M. Methodological Insights on Biomarker-Based Patient Selection: A Review of Scientific Advice Procedures at the European

Medicines Agency. Clinical Pharmacology & Therapeutics. 2025;117(5):1226-35. https://doi.org/10.1002/cpt.3558.

82. Kemp-Harper BK, Velagic A, Paolocci N, Horowitz JD, Ritchie RH. Cardiovascular therapeutic potential of the redox siblings, nitric oxide (NO•) and Nitroxyl (HNO), in the setting of reactive oxygen species dysregulation. Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications. 2020:311-37. https://doi.org/10.1007/164_2020_389.

83. Minichmayr I, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Advanced drug delivery reviews. 2024;215:115421. https://doi.org/10.1016/j.addr.2024.115421.

84.Ghimire K, Altmann HM, Straub AC, Isenberg JS. Nitric oxide: what's new to NO? American Journal of Physiology-Cell Physiology. 2017;312(3):C254-C62. https://doi.org/10.1152/ajpcell.00315.2016